Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... InspireMD, Inc. (NYSE MKT: NSPR) ("InspireMD" or the "Company"), ... that its CGuard TM Embolic Prevention System reported positive ... Musialek , at the EuroPCR conference on May ... PARADIGM, an investigator-initiated P rospective evaluation of ... revascularization I n symptomatic and increased-risk asymptomatic carotid artery ...
(Date:5/22/2015)... Richmond Pharmacology is a ... a worldwide reputation for excellence in clinical trials. ... peer reviewed medical journals. Its officers are engaged ... discussions about rules for transparency and publication of ... , Clinical research is conducted worldwide, ...
(Date:5/21/2015)... CHICAGO , May 21, 2015 /PRNewswire-USNewswire/ ... lump along the side of his neck, ... and took a couple weeks off from ... didn,t go away.                               ... Rendino, 26, was referred to Michel ...
Breaking Medicine Technology:InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 2InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 3InspireMD's CGuardTM Highlighted at Clinical Presentation at EuroPCR 2015 Conference 4Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
... LAWRENCE, Mass., Nov. 9, 2010 NxStage Medical, ... manufacturer of innovative dialysis products, today announced that ... Brown, Chief Financial Officer, will participate in the ... Healthcare Summit Boston Harbor Hotel Boston, MATuesday, November ...
... ATLANTA, Nov. 9, 2010 The addition of ... associated with a rapid clinical response, improved function ... of adult rheumatoid arthritis (RA) patients reflecting those ... prior TNF-inhibitor use).  These positive clinical trial data ...
Cached Medicine Technology:NxStage Announces Fourth Quarter 2010 Investor Conference Schedule 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 2New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 3New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 4New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 5New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 6New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 7New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 8New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 9New Cimzia® (certolizumab pegol) Data Show a Significant, Rapid Clinical Response and Reduced Disease Activity Among Diverse Patient Populations With Active Rheumatoid Arthritis (RA) 10
(Date:5/25/2015)... New York, New York (PRWEB) May 25, 2015 ... and distributor of patented products, launches the Big Little ... ability to customize the perfect table that will suit ... reached a whopping revenue of $646 billion this past ... billion a year industry" says Scott J. Cooper, CEO ...
(Date:5/25/2015)... HomeCare is proud to announce that David Allerby, Co-Founder ... Iwamoto, Co-Founder & CMO, are Finalists for the Ernst ... Greater Los Angeles. The award is presented by EY ... and a personal commitment to their communities. , “Our ... of our organization,” said Co-Founder & CEO, David Allerby, ...
(Date:5/25/2015)... MA (PRWEB) May 25, 2015 A recent ... 2015 states 1,000 persons have died as a direct result ... 2014. This marks a 33% rise in overdose deaths attributed ... Charlie Baker, “This issue doesn’t care about geography. This issue ... This issue doesn’t care about class.” As the state of ...
(Date:5/25/2015)... May 25, 2015 Thousands of ... move forward in the federal multidistrict litigation now ... Texas. According to a Motion filed on May ... modify the Case Management Order pertaining to the ... things, the Motion seeks the adoption of a ...
(Date:5/25/2015)... CA (PRWEB) May 25, 2015 Join Fiona's ... a free two-hour instructional clinic. Irish National Player, Fiona ... and give them a taste of her coaching style. Fiona ... and Novato. Camps in Novato are at Lynwood Elmentary School ... , Novato High School - June 6th, 2015 - 1:00-3:00pm. ...
Breaking Medicine News(10 mins):Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 2Health News:Party Time - Top Officials Get Excited About World Patent Marketing's New Party Invention For Entertainment 3Health News:24Hr HomeCare Co-Founders Named Finalists for EY Entrepreneur of the Year 2015 Awards 2Health News:Opioid Deaths Increase by 33 Percent Since 2012 in Mass. 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2
... and even old socks litter the shores of Lau Fau ... of the territory's oyster farming industry. From across the ... over Deep Bay, one of Hong Kong's most polluted stretches ... handed back to the Chinese, pollution is one of the ...
... having mood swings, and stays out late, then it could very ... ,The finding is based on a new research by ... on 107 adolescents with an average age of 17.98 years. ... were in love, and were experiencing intense romantic love, while the ...
... that around 350, 000 British senior citizens ... . , The major survey carried out by the ... by the Department of Health and Comic Relief is the first ... report titled: UK Study of Abuse and Neglect, found that 4 ...
... Schwarzenegger will call on British Prime Minister Tony Blair ... ,The California Governor wanted to work with ... warming, said a source close to Blair. ... speeches for when Mr Blair retires on June 27, ...
... Researchers at the University of Illinois at Chicago and ... silenced genes in patients who suffer from Neurodegenerative diseases ... stroke, certain cellular events take place that lead to ... group of enzymes called histone deacetylases can modulate gene ...
... restricted only to difficulty in walking on a uneven stretch, ... high heels are also making driving dangerous for over 12 ... footwear for driving and said that women are actually risking ... conducted by women's car insurance concern Sheilas Wheels revealed that ...
Cached Medicine News:Health News:Hong Kong Choked by Growing Pollution Problem 2Health News:Hong Kong Choked by Growing Pollution Problem 3Health News:Researchers Developing New Therapy to Re-activate Silenced Genes 2
Inquire...
Inquire...
Inquire...
... first time, the Integrated Cytometry Solution ... post-analytical solution coupled with complete LIS ... steps a sample undergoes - and ... one - it delivers a progressive ...
Medicine Products: